Skip to content
Main Navigation
About us
Company profile
Our values
Our strategy
Board of Directors
Senior management
Our history
Research and development
Technology platform
Therapeutic areas
Pipeline
Scientific papers and presentations
Partnering
Our approach
Our partnerships
Investors
Financial reports and presentations
Share information
Analyst coverage
Major shareholders
Financial calendar
Corporate governance
Corporate governance statements
Dividend policy
Annual general meeting
Articles of association
Safe harbour statement
Whistleblower policy
Risk management
Investor relations policy
ESG
Email alerts
Media
News and announcements
Image library
Glossary
Email alerts
Careers
Life at Nykode
Meet us
Open positions
Search
Media
News and Announcements
Newest first
Oldest first
Announcements
News
Search
Reset
04/10/2021
Vaccibody to participate at Guggenheim Securities’ 2nd Annual Vaccine and Infectious Disease Days
12/07/2021
Vaccibody enters into worldwide license agreement with Adaptive Biotechnologies for clinically validated SARS-CoV-2 T cell epitopes to combine in a second-generation T cell vaccine candidate to specifically address emerging SARS-CoV-2 variants of concern
29/06/2021
Vaccibody to initiate a phase 1/2 trial to evaluate two second-generation SARS CoV-2 virus DNA vaccine candidates to address emerging variants of concern
10/06/2021
Vaccibody to present at Goldman Sachs 42nd Annual Global Healthcare Conference
01/06/2021
Vaccibody to present at Jefferies Virtual Healthcare Conference (June 1-4, 2021)
Pages:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
Load more
Sorry, nothing found in this query
Privacy statement
Cookie policy
Disclaimer